Cover Image

HARDBACK
$52.95



View/Hide Left Panel

Table A12–3 Health Care Costs Associated with Influenza A and B Disease

 

% with Care

Cost per Unit

Units per Case

Form of Treatment

Moderate to severe respiratory illness

 

bed rest

50%

$50

1.0

physician a

 

20%

$50

1.0

medication b

100%

$10

1.0

medication a

discomfort following bed rest

50%

$10

1.0

medication a

Respiratory illness with sinusitis

 

bed rest

50%

$50

1.0

physician a

 

20%

$50

1.0

medication b

100%

$10

1.0

medication a

sinusitis

50%

$50

1.0

medication b

 

100%

$10

1.0

medication a

discomfort following bed rest

50%

$50

1.0

physician a

Respiratory illness with post-influenza fatigue

 

bed rest

50%

$50

1.0

physician a

 

50%

$50

1.0

medication b

100%

$10

1.0

medication a

discomfort following bed rest

50%

$10

1.0

medication a

post-influenza fatigue

50%

$50

1.0

physician a

Pneumonia

 

acute care and ICU together

100%

$50

1.0

physician a

percentage of cases adjusted

100%

$4,000

1.0

hospitalization

 

100%

$100

1.0

physician b

100%

$100

1.0

diagnostic b

recuperation

100%

$50

1.0

physician a

 

100%

$50

1.0

medication b

100%

$10

1.0

medication a

VACCINE DEVELOPMENT

The committee assumed that it will take 7 years until licensure of a influenza vaccine and that $360 million needs to be invested. The committee assumed that the licensed vaccine would most likely be a DNA vaccine requiring immunization every 5 years. Table 4–1 summarizes vaccine development assumptions for all vaccines considered in this report.



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement